Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 4Withdrawn 3Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Insulin Resistance 3Diabetes Mellitus, Type 2 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Pioglitazone × Genitourinary × Clear all
NCT05098327 2023-08-15

Pioglitazone and Insulin Resistance in ADT

State University of New York at Buffalo

Phase 3 Withdrawn
Genitourinary

Diabetes Mellitus, Type 2, Insulin Resistance, Prostatic Neoplasms

NCT04995978 2023-06-23

Insulin Resistance and Androgen Deprivation Therapy

St. Louis University

Phase 2 Withdrawn
Genitourinary

Insulin Resistance, Prostatic Neoplasms

NCT04658849 2023-05-15

Insulin Resistance Following ADT for Prostate CA

St. Louis University

Phase EARLY_PHASE1 Withdrawn
Genitourinary

Insulin Resistance, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡